title: BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial.
abstract: Vitamin D receptor (VDR) gene polymorphisms could be considered one of the factors influencing the efficacy of the anti-osteoporotic treatments. In this multicenter, prospective, randomized and controlled trial we evaluated whether BsmI vitamin D receptor (VDR) genotypes influence the efficacy of antiresorptive treatment regimes (administered alone or in combination) in postmenopausal osteoporotic women. Using restriction endonuclease, we identified the BsmI VDR polymorphism in 1,100 postmenopausal women with osteoporosis. The women were randomized, taking account of genotype, into five treatment groups: (1) alendronate (Aln, 10 mg/day) plus raloxifene (Rlx, 60 mg/day); (2) Aln plus hormone replacement therapy (HRT, 0.625 mg/day conjugated equine estrogens plus 2.5 mg/day medroxyprogesterone acetate); (3) Aln alone; (4) HRT alone; and (5) Rlx alone. Lumbar-spine bone mineral density (BMD) and bone turnover markers were measured at study entry and after 1 year of treatment. Using the general linear model (GLM) repeated-measures procedure, the means of BMD and bone turnover markers significantly differed from baseline after a period of treatment. In particular, the mean change from baseline for BMD was -0.034 (95% confidence interval [CI]: -0.037 to -0.031, P <0.001); for serum osteocalcin (OC) it was 1.369 (95% CI: 1.289 to 1.448, P <0.001); and for urinary deoxypyridinoline (DPD) it was 1.322 (95% CI: 1.242 to 1.401, P <0.001), indicating a considerable variation before and after treatment of these indicators. In all three cases these effects appeared significantly influenced by treatments, genotypes, and the treatments*genotypes interaction term (P <0.001 each, except for the BMD and genotype effect with P =0.02), and not by the investigational centers involved in the study. In conclusion, in postmenopausal osteoporotic women, BsmI VDR genotypes influence the efficacy of antiresorptive drugs particularly when used in combination.
authors.affiliation: Department of Obstetrics and Gynaecology, University Magna Graecia of Catanzaro, Catanzaro, Italy. stefanopalomba@tin.it
authors.forename: Stefano
authors.initials: S
authors.lastname: Palomba
authors.forename: Francesco
authors.initials: F
authors.lastname: Orio
authors.forename: Tiziana
authors.initials: T
authors.lastname: Russo
authors.forename: Angela
authors.initials: A
authors.lastname: Falbo
authors.forename: Achille
authors.initials: A
authors.lastname: Tolino
authors.forename: Francesco
authors.initials: F
authors.lastname: Manguso
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Nunziata
authors.forename: Pasquale
authors.initials: P
authors.lastname: Mastrantonio
authors.forename: Gaetano
authors.initials: G
authors.lastname: Lombardi
authors.forename: Fulvio
authors.initials: F
authors.lastname: Zullo
mesh_terms: D000284:Administration, Oral; D000368:Aged; D019386:Alendronate / Q000008:administration & dosage / Q000009:adverse effects; D015519:Bone Density / Q000187:drug effects / Q000235:genetics; D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001862:Bone Resorption / Q000517:prevention & control*; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D004966:Estrogens, Conjugated (USP) / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D005838:Genotype; D020249:Hormone Replacement Therapy / Q000009:adverse effects / Q000379:methods; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage* / Q000009:adverse effects; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy / Q000235:genetics*; D011446:Prospective Studies; D020849:Raloxifene Hydrochloride / Q000008:administration & dosage / Q000009:adverse effects; D018167:Receptors, Calcitriol / Q000235:genetics*; D020845:Selective Estrogen Receptor Modulators / Q000008:administration & dosage / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D050071:Bone Density Conservation Agents; D004338:Drug Combinations; D004966:Estrogens, Conjugated (USP); D018167:Receptors, Calcitriol; D020845:Selective Estrogen Receptor Modulators; D020849:Raloxifene Hydrochloride; D017258:Medroxyprogesterone Acetate; D019386:Alendronate
references.citation: Endocr Rev. 1999 Dec;20(6):788-804
references.pmid: 10605626
references.citation: N Engl J Med. 1997 Jul 10;337(2):77-82
references.pmid: 9211676
references.citation: Endocrinology. 2000 Aug;141(8):2829-36
references.pmid: 10919269
references.citation: J Clin Endocrinol Metab. 2002 Apr;87(4):1502-8
references.pmid: 11932272
references.citation: Hum Genet. 1998 Nov;103(5):576-85
references.pmid: 9860300
references.citation: Nature. 1994 Jan 20;367(6460):284-7
references.pmid: 8161378
references.citation: Calcif Tissue Int. 1995 Dec;57(6):430-5
references.pmid: 8581875
references.citation: J Clin Endocrinol Metab. 1995 Dec;80(12):3657-61
references.pmid: 8530616
references.citation: J Clin Endocrinol Metab. 1995 Sep;80(9):2800-5
references.pmid: 7673427
references.citation: J Bone Miner Res. 2002 Jan;17(1):1-10
references.pmid: 11771654
references.citation: J Clin Endocrinol Metab. 2002 Aug;87(8):3609-17
references.pmid: 12161484
references.citation: J Clin Endocrinol Metab. 2000 Feb;85(2):720-6
references.pmid: 10690882
references.citation: J Clin Endocrinol Metab. 1999 Sep;84(9):3076-81
references.pmid: 10487668
references.citation: Endocr Rev. 2002 Feb;23(1):16-37
references.pmid: 11844743
references.citation: J Clin Endocrinol Metab. 2002 Mar;87(3):983-4
references.pmid: 11889148
references.citation: Osteoporos Int. 1999;10(4):303-6
references.pmid: 10692979
references.citation: JAMA. 2001 Apr 18;285(15):1996-9
references.pmid: 11308437
references.citation: JAMA. 2000 Mar 8;283(10):1318-21
references.pmid: 10714731
references.citation: Am J Obstet Gynecol. 1999 May;180(5):1115-20
references.pmid: 10329864
references.citation: Lancet. 1995 Feb 18;345(8947):423-4
references.pmid: 7853953
references.citation: Calcif Tissue Int. 1997 May;60(5):430-3
references.pmid: 9115160
references.citation: J Bone Miner Res. 1997 Jul;12(7):1049-57
references.pmid: 9200004
references.citation: Endocr Rev. 1998 Feb;19(1):80-100
references.pmid: 9494781
references.citation: Endocrinology. 1992 May;130(5):2597-601
references.pmid: 1315250
references.citation: Hum Reprod. 2000 Oct;15(10):2087-92
references.pmid: 11006178
references.citation: Drugs. 2001;61(7):999-1039
references.pmid: 11434454
references.citation: Lancet. 2002 Jun 8;359(9322):2018-26
references.pmid: 12076571
references.citation: J Bone Miner Res. 1997 Aug;12(8):1241-5
references.pmid: 9258754
references.citation: J Clin Endocrinol Metab. 1998 Mar;83(3):939-44
references.pmid: 9506753
references.citation: J Bone Miner Res. 1995 Apr;10 (4):518-23
references.pmid: 7610921
references.citation: J Clin Endocrinol Metab. 1990 Apr;70(4):1202-7
references.pmid: 2318940
references.citation: JAMA. 2003 May 21;289(19):2525-33
references.pmid: 12759324
references.citation: Drug Metab Dispos. 2001 Apr;29(4 Pt 2):505-12
references.pmid: 11259341
references.citation: Am J Med. 2002 Mar;112(4):281-9
references.pmid: 11893367
references.citation: J Clin Endocrinol Metab. 2002 Mar;87(3):985-92
references.pmid: 11889149
references.citation: Cancer. 2000 Jun 15;88(12 Suppl):2961-78
references.pmid: 10898340
references.citation: Am J Clin Nutr. 1997 Mar;65(3):798-802
references.pmid: 9062532